CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders
Bionano Genomics, Inc. (BNGO)
Last bionano genomics, inc. earnings: 8/8 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. According to the preliminary determination, CMS will crosswalk to a previously established proprietary laboratory analyte (PLA) code for OGM, which is priced at $1263.53. Pricing at this level is $363.53 higher than 81228 and $103.53 higher than 81229, comparative codes that apply to use of microarrays and is listed on the clinical lab fee schedule (CLFS) at $900 (81228) and $1160 (81229). CPT codes for OGM are key components for obtaining r
Show less
Read more
Impact Snapshot
Event Time:
BNGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNGO alerts
High impacting Bionano Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
BNGO
News
- Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies [Yahoo! Finance]Yahoo! Finance
- Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic MalignanciesGlobeNewswire
- Bionano Genomics (NASDAQ:BNGO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Bionano Genomics (NASDAQ:BNGO) had its "sell (e)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Earnings To Watch: Bionano Genomics Inc (BNGO) Reports Q3 2025 Result [Yahoo! Finance]Yahoo! Finance
BNGO
Analyst Actions
- 11/24/25 - HC Wainwright
BNGO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- BNGO's page on the SEC website